Hexarelin induced growth hormone release is influenced by exogenous growth hormone

Plain-language guide to PMID 8548947 (1995): randomized controlled trial study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

Key Facts

PMID: 8548947
Journal: Clinical endocrinology
Year: 1995
Study type: Randomized Controlled Trial
Authors: Massoud AF et al. (3 authors)
DOI: 10.1111/j.1365-2265.1995.tb02927.x

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

Growth hormone releasing peptides (GHRPs) are a group of synthetic compounds capable of releasing GH by an unknown mechanism.

The aim of this study was to determine the effect of administering biosynthetic human growth hormone (rhGH) on the GH releasing activity of hexarelin, a new and potent GHRP, and to compare the results with those obtained with growth hormone releasing hormone (GHRH).

Who Took Part

PubMed indexes the participants as adults, men only.

Each subject underwent six studies performed in a random order and separated by at least 2 days.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Boluses of saline or rhGH were administered intravenously, followed 90 minutes later by a second intravenous bolus of saline, hexarelin or GHRH.

Studies were performed following an overnight fast.

Serum GH and IGF-I levels were measured by radioimmunoassay.

What Was Measured

The subject headings attached to it are Feedback, Growth Hormone, Growth Hormone-Releasing Hormone, Growth Substances, Hormones, Insulin-Like Growth Factor I and Oligopeptides.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1995 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.

Hexarelin: A potent synthetic hexapeptide GH secretagogue, also studied for direct heart effects via the CD36 receptor.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.